You obviously don't understand how drug pricing works in the various countries.
Firstly, getting TGA approval couldn't have happened much earlier than FDA. Still have to submit the filing and they just announced new efficacy and biomarker data in Sept to accommodate an AA pathway.
Secondly, once you've established a lower negotiated price with TGA (single payor system), then you've compromised the pricing in the US. It's always better to start high and work your way lower as needed.
Market Data 
Markets 
AI
